Tissue Repair Ltd has released a press release.
FDA Response Clarifies Path to Phase 3 Trials
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Tissue Repair
- Second US Patent granted for Glucoprime
- Appendix 4E and Annual Report 30 June 2022
- Lodgement of Type C Meeting Request with US FDA
- Tissue Repair Announces USA Patent Approval
- Appendix 4D and Half Year Report to 31 December 2021
Later from Tissue Repair
- TR Pro accepted for peer reviewed journal publication
- Appendix 4D and Half Year Report to 31 December 2022
- Update on Cash Held with Silicon Valley Bank
- Bank Deposits At SVB Available Tuesday 14 March 2023 AEDT
- FDA clears TR-987 to progress to Phase 3
Follow Tissue Repair into a list and get an email when it puts out news.
Follow Tissue Repair